Local delivery of a cancer-favoring oncolytic vaccinia virus via poly (lactic-co-glycolic acid) nanofiber for theranostic purposes

Int J Pharm. 2018 Dec 1;552(1-2):437-442. doi: 10.1016/j.ijpharm.2018.10.020. Epub 2018 Oct 9.

Abstract

Local delivery of viruses via nanomaterials has been demonstrated in the treatment of colon cancer. A cancer-favoring oncolytic vaccinia virus (CVV), which is an evolutionary cancer-favoring engineered vaccinia virus carrying the green fluorescent protein (GFP) gene, has antitumor efficacy in drug-resistant colon cancer and metastatic liver cells. Here, we present the antitumor efficacy of a CVV coated a poly lactic-co-glycolic acid (PLGA) nanofiber for local drug delivery in theranostic approaches. In vitro- and in vivo-based analyses using mouse colon carcinoma models confirmed the therapeutic efficacy of CVV-PLGA nanofibers through diagnostic localization of the tumors and reduced tumor burden as a result of enhanced apoptosis. We propose that the CVV-PLGA nanofiber may be used for theranostic purposes in cancer therapy.

Keywords: Cancer therapy; Cancer-favoring oncolytic vaccinia virus; Poly (lactic-co-glycolic acid) nanofibers; Theranostics.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Colonic Neoplasms / pathology
  • Colonic Neoplasms / therapy*
  • Mice, Nude
  • Nanofibers / administration & dosage*
  • Oncolytic Viruses*
  • Polylactic Acid-Polyglycolic Acid Copolymer / administration & dosage*
  • Theranostic Nanomedicine
  • Tumor Burden
  • Vaccinia virus*

Substances

  • Polylactic Acid-Polyglycolic Acid Copolymer